Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leptin: from animals to humans.

Murielle M Veniant1, Carl P LeBel

  • 1Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA, USA.

Current Pharmaceutical Design
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.

Journal of medicinal chemistry·2026
Same author

GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale.

Diabetes·2025
Same author

GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.

Nature metabolism·2025
Same author

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.

Nature metabolism·2024
Same author

A transcriptomic and proteomic atlas of obesity and type 2 diabetes in cynomolgus monkeys.

Cell reports·2023
Same author

GIPR gene expression in testis is mouse specific and can impact male mouse fertility.

Andrology·2022
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Leptin impacts metabolism and body weight through both central and direct peripheral actions. Leptin therapy is most effective in correcting leptin deficiency, improving insulin resistance and appetite.

Area of Science:

  • Endocrinology and Metabolism
  • Neuroendocrinology
  • Molecular Biology

Background:

  • Leptin, a hormone primarily known for regulating energy balance, exhibits diverse peripheral effects.
  • These effects are mediated through central nervous system pathways and direct actions on target tissues.
  • Leptin's role extends beyond obesity to influence diabetes, appetite, thermogenesis, immunity, and reproduction.

Purpose of the Study:

  • To review preclinical evidence of leptin's direct effects on specific tissues (neurons, liver, muscle) and metabolic pathways.
  • To examine clinical evidence of leptin's effects, particularly recombinant human leptin, in various patient populations.
  • To assess leptin's therapeutic potential in states of leptin deficiency versus conditions with measurable serum leptin.

Main Methods:

Related Experiment Videos

  • Review of preclinical studies investigating direct leptin actions on cellular and molecular targets.
  • Analysis of clinical trial data and case studies involving recombinant human leptin administration.
  • Comparison of leptin's efficacy in lean, obese, diabetic individuals, and those with congenital leptin deficiency or lipoatrophic diabetes.

Main Results:

  • Preclinical data support direct metabolic effects of leptin in key tissues like the liver and muscle.
  • Clinical studies show profound benefits of leptin treatment in patients with congenital leptin deficiency, including weight loss and improved insulin sensitivity.
  • Obese and diabetic subjects with normal or elevated leptin levels did not exhibit significant improvements with leptin therapy.

Conclusions:

  • Leptin exerts direct metabolic effects on peripheral tissues, expanding its known physiological functions.
  • Leptin replacement therapy is highly effective in treating conditions characterized by leptin deficiency.
  • Targeted leptin therapy holds promise for specific metabolic disorders, highlighting the importance of assessing endogenous leptin levels.